Navigation
The Company
Our Science
mTOR Pathway
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Contact Us
General Contact
For Healthcare Professionals
Careers
Archive: November, 2020
Home
2020
November
20
Nov
2020
Long-Term Follow-Up from AMPECT, an Open-Label Phase 2 Registration Trial of
nab
-Sirolimus for Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
0
0
November 20, 2020
November 20, 2020